References
- Chio WL. (1981). The physiological significance of the apparent volume of distribution, Vdarea or Vdβ, in pharmacokinetic studies. Res Commun Chem Pathol Pharmacol 33:499–508
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
- Hamada M, Takeuchi T, Kondo S, et al. (1970). A new antibiotic, negamycin. J Antibiot 23:170–1
- Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–79
- Kwon JY, Moini M. (2001). Analysis of underivatized amino acid mixtures using high performance liquid chromatography/dual oscillating nebulizer atmospheric pressure microwave induced plasma ionization-mass spectrometry. J Am Soc Mass Spectrom 12:117–22
- Lin JH. (1998). Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26:1202–12
- Maeda K, Ohno M. (1979). Chemical studies on antibiotics and other bioactive microbial products by Prof. Hamao Umezawa. Heterocycles 13:49–78
- Mahmood I, Balian JD. (1996). Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species. Life Sci 59:579–85
- Metushi IG, Cai P, Zhu X, et al. (2011). A fresh look at the mechanism of isoniazid-induced hepatoxicity. Clin Pharm Ther 89:911–14
- Mizuno S, Nitta K, Umezawa H. (1970a). Mechanism of action of negamycin in Escherichia coli K12. II. Miscoding activity in polypeptide synthesis directed by synthetic polypeptide. J Antibiot 23:589–94
- Mizuno S, Nitta K, Umezawa H. (1970b). Mechanism of action of negamycin in Escherichia coli K12. I. Inhibition of initiation of protein synthesis. J Antibiot 23:581–8
- Oie S, Tozer TN. (1979). Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 68:1203–5
- Olivier NB, Altman RB, Noeske J, et al. (2014). Negamycin induces translational stalling and miscoding by binding to the small subunit head domain of the Escherichia coli ribosome. Proc Natl Acad Sci USA 111:16274–9
- Paine SW, Menochet K, Denton R, et al. (2011). Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. Drug Metab Dispos 39:1008–13
- Polikanov YS, Szal T, Jiang F, et al. (2014). Negamycin interferes with decoding and translocation by simulatneous interaction with rRNA and tRNA. Mol Cell 56:541–50
- Raju B, Mortell K, Anandan S, et al. (2003). N- and C-terminal modifications of negamycin. Bioorg Med Chem Lett 13:2413–18
- Reck F, Alm R, Brassil P, et al. (2011). Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad spectrum antibacterial agents with reduced hERG activity. J Med Chem 54:7834–47
- Toutain PL, Bousquet-Melou B. (2004a). Volumes of distribution. J Vet Pharmacol Ther 27:441–53
- Toutain PL, Bousquet-Melou A. (2004b). Plasma terminal half-life. J Vet Pharmacol Ther 27:427–39
- Waring MJ. (2010). Lipophilicity in drug discovery. Expert Opin Drug Discov 5:235–48
- Waters NJ, Lombardo F. (2010). Use of the Oie-Tozer model in understanding mechanisms and determinants of drug distribution. Drug Metab Dispos 38:1159–65
- Zhang M, Zhou D, Wang Y, et al. (2011). Preclinical pharmacology and pharmacokinetics of AZD3783, a selective 5-hydroxytryptamine 1B receptor antagonist. J Pharmacol Exp Ther 339:567–78